1. Home
  2. ARTL vs ONCO Comparison

ARTL vs ONCO Comparison

Compare ARTL & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ARTL

Artelo Biosciences Inc.

N/A

Current Price

$3.45

Market Cap

2.5M

Sector

Health Care

ML Signal

N/A

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$0.67

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARTL
ONCO
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5M
3.0M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
ARTL
ONCO
Price
$3.45
$0.67
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.3M
★ 4.6M
Earning Date
11-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 22.80
EPS
★ N/A
N/A
Revenue
N/A
★ $815,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.52
$0.09
52 Week High
$19.91
$6.73

Technical Indicators

Market Signals
Indicator
ARTL
ONCO
Relative Strength Index (RSI) 45.55 44.24
Support Level $3.20 $0.54
Resistance Level $6.81 $0.98
Average True Range (ATR) 1.26 0.15
MACD -0.30 -0.01
Stochastic Oscillator 0.16 6.62

Price Performance

Historical Comparison
ARTL
ONCO

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: